MARKET

ESPR

ESPR

Esperion Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.00
-0.57
-1.48%
After Hours: 38.00 0 0.00% 17:00 08/07 EDT
OPEN
38.49
PREV CLOSE
38.57
HIGH
39.11
LOW
37.94
VOLUME
645.61K
TURNOVER
--
52 WEEK HIGH
76.98
52 WEEK LOW
24.82
MARKET CAP
1.05B
P/E (TTM)
-3.9446
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ESPR stock price target is 87.73 with a high estimate of 191.00 and a low estimate of 42.00.

EPS

ESPR News

More
Were Hedge Funds Right About Betting On Esperion Therapeutics (ESPR)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 1d ago
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on August 10, 2020. Following the release, company management will ho
GlobeNewswire · 5d ago
Esperion Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold
On Thursday, Esperion Therapeutics got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. While Esperion Therapeutics is not near an ideal entry right now, see if it manages to form and break out of a proper consolidation. Esperion Therapeutics
Investor's Business Daily · 07/16 23:16
Esperion Therapeutics Option Alert: Jul 17 $55 Calls at the Ask: 850 @ $1.0 vs 493 OI; Earnings 8/6 Before Open [est] Ref=$51.13
Benzinga · 07/06 15:23
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets
GlobeNewswire · 07/01 16:12
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets
ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering
Benzinga · 07/01 15:12
Esperion Therapeutics: An Easy Double, Maybe A Lot More
Seeking Alpha - Article · 06/26 05:43
Esperion Therapeutics, Inc. (ESPR): Hedge Funds Are Getting Bullish
Insider Monkey · 06/23 16:42

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About ESPR

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.
More

Webull offers kinds of Esperion Therapeutics Inc stock information, including NASDAQ:ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.